Protection against cervical cancer versus decreasing harms from screening — What would U.S. patients and clinicians prefer, and do their preferences matter?

Preventive Medicine

Volumn 98, Issue , 2017, Pages 31-32

  Kinney, Walter K ^a   Huh, Warner K ^b  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cancer; Cervix; HPV; Screening

Indexed keywords

ARTICLE; CANCER PREVENTION; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; COLPOSCOPY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; LYMPH NODE DISSECTION; LYMPHEDEMA; PATIENT HARM; PATIENT PREFERENCE; PHYSICIAN ATTITUDE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; FEMALE; HARM REDUCTION; HEALTH PERSONNEL ATTITUDE; ISOLATION AND PURIFICATION; PAPILLOMAVIRIDAE; PREVENTIVE MEDICINE; TIME FACTOR; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ATTITUDE OF HEALTH PERSONNEL; FEMALE; HARM REDUCTION; HUMANS; PAPILLOMAVIRIDAE; PATIENT PREFERENCE; PREVENTIVE MEDICINE; TIME FACTORS; UNITED STATES; UTERINE CERVICAL NEOPLASMS;

EID: 85014525288     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2016.12.041     Document Type: Article

References (10)

1. ACOG, Committee opinion. Recommendations on frequency of Pap test screening. Number 152–March 1995. Committee on Gynecologic Practice. American College of Obstetricians and Gynecologists. Int. J. Gynaecol. Obstet. 49 (1995), 210–211 May.
2. ACOG, Practice bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). ACOG Committee on Practice Bulletins. Obstet. Gynecol. 102:2 (2003 Aug), 417–427.
3. Committee on Practice Bulletins—Gynecology, ACOG practice bulletin number 131: screening for cervical cancer. Obstet. Gynecol. 120 (2012), 1222–1238 Nov.
4. Farrell, R., Gebski, V., Hacker, N.F., Quality of life after complete lymphadenectomy for vulvar cancer: do women prefer sentinel lymph node biopsy?. Int. J. Gynecol. Cancer 24 (2014), 813–819 May.
5. Gage, J.C., Schiffman, M., Katki, H.A., Castle, P.E., Fetterman, B., Wentzensen, N., Poitras, N.E., Lorey, T., Cheung, L.C., Kinney, W.K., Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J. Natl. Cancer Inst., 18, 2014 Jul, 106.
6. Kinney, W., Wright, T.C., Dinkelspiel, H.E., DeFrancesco, M., Thomas Cox, J., Huh, W., Increased cervical cancer risk associated with screening at longer intervals. Obstet. Gynecol. 125 (2015 Feb), 311–315.
7. Saslow, D., Solomon, D., Lawson, H.W., Killackey, M., Kulasingam, S.L., Cain, J.M., Garcia, F.A., Moriarty, A.T., Waxman, A.G., Wilbur, D.C., Wentzensen, N., Downs, L.S. Jr., Spitzer, M., Moscicki, A.B., Franco, E.L., Stoler, M.H., Schiffman, M., Castle, P.E., Myers, E.R., Chelmow, D., Herzig, A., Kim, J.J., Kinney, W., Herschel, W.L., Waldman, J., American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J. Low. Genit. Tract Dis. 16 (2012), 175–204 Jul.
8. Silver, M.I., Schiffman, M., Fetterman, B., Poitras, N.E., Gage, J.C., Wentzensen, N., Lorey, T., Kinney, W.K., Castle, P.E., The population impact of human papillomavirus/cytology cervical cotesting at 3-year intervals: reduced cervical cancer risk and decreased yield of precancer per screen. Cancer 122:23 (2016 Dec 1), 3682–3686.
9. Tota, J.E., Bentley, J., Blake, J., Coutlee, F., Duggan, M.A., Ferenczy, A., Franco, E.L., Fung, M., Gotlieb, W., Mayrand, M.H., McLachlin, M., Murphy, J., Ogilvie, G., Ratnam, S., Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev. Med. 98 (2017), 5–14.
10. Wright, T.C. Jr., Schiffman, M., Solomon, D., Cox, J.T., Garcia, F., Goldie, S., Hatch, K., Noller, K.L., Roach, N., Runowicz, C., Saslow, D., Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103 (2004 Feb), 304–309.